Print

Spherix (SPEX) and Fullife Healthcare Sign Supply and License Agreement for D-Tagatose in Nutraceutical Products in India  
11/16/2012 7:17:44 AM

BETHESDA, Md. and MUMBAI, India, Nov. 15, 2012 (GLOBE NEWSWIRE) -- Spherix Incorporated (Nasdaq:SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – and Fullife Healthcare Pvt. Ltd. – an innovation-driven company focused on bringing unique healthcare solutions to India – today announced the signing of a supply and license agreement for the use of D-tagatose in nutraceutical products in India.
//-->